167 related articles for article (PubMed ID: 24683542)
1. Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma.
Scognamiglio I; Di Martino MT; Campani V; Virgilio A; Galeone A; Gullà A; Gallo Cantafio ME; Misso G; Tagliaferri P; Tassone P; Caraglia M; De Rosa G
Biomed Res Int; 2014; 2014():217365. PubMed ID: 24683542
[TBL] [Abstract][Full Text] [Related]
2. In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma.
Di Martino MT; Campani V; Misso G; Gallo Cantafio ME; Gullà A; Foresta U; Guzzi PH; Castellano M; Grimaldi A; Gigantino V; Franco R; Lusa S; Cannataro M; Tagliaferri P; De Rosa G; Tassone P; Caraglia M
PLoS One; 2014; 9(2):e90005. PubMed ID: 24587182
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Characterization of Aptamer-Targeted SNALPs for the Delivery of siRNA.
Wilner SE; Levy M
Methods Mol Biol; 2016; 1380():211-24. PubMed ID: 26552829
[TBL] [Abstract][Full Text] [Related]
4. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.
Di Martino MT; Leone E; Amodio N; Foresta U; Lionetti M; Pitari MR; Cantafio ME; Gullà A; Conforti F; Morelli E; Tomaino V; Rossi M; Negrini M; Ferrarini M; Caraglia M; Shammas MA; Munshi NC; Anderson KC; Neri A; Tagliaferri P; Tassone P
Clin Cancer Res; 2012 Nov; 18(22):6260-70. PubMed ID: 23035210
[TBL] [Abstract][Full Text] [Related]
5. Transferrin-decorated thymoquinone-loaded PEG-PLGA nanoparticles exhibit anticarcinogenic effect in non-small cell lung carcinoma via the modulation of miR-34a and miR-16.
Upadhyay P; Sarker S; Ghosh A; Gupta P; Das S; Ahir M; Bhattacharya S; Chattopadhyay S; Ghosh S; Adhikary A
Biomater Sci; 2019 Oct; 7(10):4325-4344. PubMed ID: 31411213
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
Huang X; Schwind S; Yu B; Santhanam R; Wang H; Hoellerbauer P; Mims A; Klisovic R; Walker AR; Chan KK; Blum W; Perrotti D; Byrd JC; Bloomfield CD; Caligiuri MA; Lee RJ; Garzon R; Muthusamy N; Lee LJ; Marcucci G
Clin Cancer Res; 2013 May; 19(9):2355-67. PubMed ID: 23493348
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines.
de Antonellis P; Liguori L; Falanga A; Carotenuto M; Ferrucci V; Andolfo I; Marinaro F; Scognamiglio I; Virgilio A; De Rosa G; Galeone A; Galdiero S; Zollo M
Naunyn Schmiedebergs Arch Pharmacol; 2013 Apr; 386(4):287-302. PubMed ID: 23354452
[TBL] [Abstract][Full Text] [Related]
8. Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma.
Cosco D; Cilurzo F; Maiuolo J; Federico C; Di Martino MT; Cristiano MC; Tassone P; Fresta M; Paolino D
Sci Rep; 2015 Dec; 5():17579. PubMed ID: 26620594
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of tumor suppressor microRNA-1 by transferrin-conjugated lipopolyplex nanoparticles to patient-derived glioblastoma stem cells.
Wang X; Huang X; Yang Z; Gallego-Perez D; Ma J; Zhao X; Xie J; Nakano I; Lee LJ
Curr Pharm Biotechnol; 2014; 15(9):839-46. PubMed ID: 25374033
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma.
Yin Y; Yang W; Zhang L; Liu K; Luo Z
Hematology; 2021 Dec; 26(1):160-169. PubMed ID: 33528317
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-34a is a tumor suppressor in choriocarcinoma via regulation of Delta-like1.
Pang RT; Leung CO; Lee CL; Lam KK; Ye TM; Chiu PC; Yeung WS
BMC Cancer; 2013 Jan; 13():25. PubMed ID: 23327670
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia.
Ng HY; Wan TS; So CC; Chim CS
J Clin Pathol; 2014 Jul; 67(7):626-31. PubMed ID: 24811488
[TBL] [Abstract][Full Text] [Related]
13. The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells.
Shi Y; Liu C; Liu X; Tang DG; Wang J
PLoS One; 2014; 9(3):e90022. PubMed ID: 24595209
[TBL] [Abstract][Full Text] [Related]
14. c-Myc, RMRP, and miR-34a-5p form a positive-feedback loop to regulate cell proliferation and apoptosis in multiple myeloma.
Xiao X; Gu Y; Wang G; Chen S
Int J Biol Macromol; 2019 Feb; 122():526-537. PubMed ID: 30389523
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia.
Wang LQ; Kwong YL; Wong KF; Kho CS; Jin DY; Tse E; Rosèn A; Chim CS
J Transl Med; 2014 Feb; 12():52. PubMed ID: 24559316
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T
Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203
[TBL] [Abstract][Full Text] [Related]
17. Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma.
Lei W; Wang S; Yang C; Huang X; Chen Z; He W; Shen J; Liu X; Qian W
Sci Rep; 2016 Aug; 6():32174. PubMed ID: 27552933
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cell proliferation and migration by chondroitin sulfate-g-polyethylenimine-mediated miR-34a delivery.
Liang S; Duan Y; Xing Z; Han H; Zhang A; Li L; Yang Y; Li Q
Colloids Surf B Biointerfaces; 2015 Dec; 136():577-84. PubMed ID: 26454548
[TBL] [Abstract][Full Text] [Related]
19. miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth.
Han Y; Meng F; Venter J; Wu N; Wan Y; Standeford H; Francis H; Meininger C; Greene J; Trzeciakowski JP; Ehrlich L; Glaser S; Alpini G
J Hepatol; 2016 Jun; 64(6):1295-304. PubMed ID: 26923637
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles.
Tivnan A; Orr WS; Gubala V; Nooney R; Williams DE; McDonagh C; Prenter S; Harvey H; Domingo-Fernández R; Bray IM; Piskareva O; Ng CY; Lode HN; Davidoff AM; Stallings RL
PLoS One; 2012; 7(5):e38129. PubMed ID: 22662276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
